744 related articles for article (PubMed ID: 23409405)
1. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
[TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
[TBL] [Abstract][Full Text] [Related]
4. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals.
Shurie JS; Deribew A
Ethiop Med J; 2010 Apr; 48(2):85-93. PubMed ID: 20608012
[TBL] [Abstract][Full Text] [Related]
6. Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
Bhutia E; Hemal A; Yadav TP; Ramesh KL
Afr Health Sci; 2014 Jun; 14(2):408-13. PubMed ID: 25320591
[TBL] [Abstract][Full Text] [Related]
7. Does first line antiretroviral therapy increase the prevalence of cardiovascular risk factors in Indian patients?: A cross sectional study.
Carey RA; Rupali P; Abraham OC; Kattula D
J Postgrad Med; 2013; 59(4):258-62. PubMed ID: 24346381
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.
Kinabo GD; Sprengers M; Msuya LJ; Shayo AM; van Asten H; Dolmans WM; van der Ven AJ; Warris A
Pediatr Infect Dis J; 2013 Jan; 32(1):39-44. PubMed ID: 23038217
[TBL] [Abstract][Full Text] [Related]
9. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.
Piloya T; Bakeera-Kitaka S; Kekitiinwa A; Kamya MR
J Int AIDS Soc; 2012 Jul; 15(2):17427. PubMed ID: 22814353
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal].
Diouf A; Cournil A;
Bull Soc Pathol Exot; 2014 Oct; 107(4):234-7. PubMed ID: 24683016
[TBL] [Abstract][Full Text] [Related]
11. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital.
Julius H; Basu D; Ricci E; Wing J; Basu JK; Pocaterra D; Bonfanti P
Curr HIV Res; 2011 Jun; 9(4):247-52. PubMed ID: 21631427
[TBL] [Abstract][Full Text] [Related]
12. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia.
Tesfaye DY; Kinde S; Medhin G; Megerssa YC; Tadewos A; Tadesse E; Shimelis T
Diabetes Metab Syndr; 2014; 8(2):102-7. PubMed ID: 24907175
[TBL] [Abstract][Full Text] [Related]
13. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Aurpibul L; Puthanakit T; Taejaroenkul S; Sirisanthana T; Sirisanthana V
Pediatr Infect Dis J; 2012 Apr; 31(4):384-8. PubMed ID: 22124211
[TBL] [Abstract][Full Text] [Related]
14. Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.
Tomazic J; Silic A; Karner P; Vidmar L; Maticic M; Poljak M; Ihan A; Janez A
Wien Klin Wochenschr; 2004 Nov; 116(21-22):755-9. PubMed ID: 15628647
[TBL] [Abstract][Full Text] [Related]
15. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
[TBL] [Abstract][Full Text] [Related]
16. [A study of HIV-related lipodystrophy syndrome in 55 HIV-infected Chinese adult patients].
Zhang L; Li M; Tao MM; Qiu ZF; Xie J; Han Y; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2009 Feb; 48(2):118-21. PubMed ID: 19549465
[TBL] [Abstract][Full Text] [Related]
17. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
18. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
Fantoni M; Del Borgo C; Autore C; Barbaro G
Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India.
Kalyanasundaram AP; Jacob SM; Hemalatha R; Sivakumar MR
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):329-34. PubMed ID: 21508297
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.
Biron A; Bobin-Dubigeon C; Volteau C; Piroth L; Perré P; Leport C; Prazuck T; Jovelin T; Billard M; Sébille V; Bard JM; Raffi F; Biron C
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1672-8. PubMed ID: 22731114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
